Lv1
30 积分 2023-01-28 加入
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics
14小时前
待确认
Dual targeting of transferrin receptor and CD98hc enhances brain exposure of large molecules
15天前
已完结
Characterization of an anti-STEAP1 T-cell dependent bispecific antibody for the treatment of prostate cancer and associated toxicity in cynomolgus monkeys
22天前
已完结
Balancing brain exposure, pharmacokinetics and safety of transferrin receptor antibodies for delivery of neuro-therapeutics
25天前
已完结
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
1个月前
已完结
Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy
1个月前
已完结
CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells
1个月前
已完结
CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells
1个月前
已完结
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
1个月前
已完结
Dual PD-1/IL-2Rα targeting restores CD8+ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC
1个月前
已完结
皖公网安备34019202002308
